BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 25256924)

  • 21. Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers.
    Perri T; Lifshitz D; Sadetzki S; Oberman B; Meirow D; Ben-Baruch G; Friedman E; Korach J
    Fertil Steril; 2015 May; 103(5):1305-12. PubMed ID: 25792249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Navigating the body of literature assessing BRCA1/2 mutations and markers of ovarian function: a systematic review and meta-analysis.
    Cordeiro Mitchell CN; McGuinness B; Fine E; Kearns WG; Christianson MS; Segars J; Pastore LM
    J Assist Reprod Genet; 2020 May; 37(5):1037-1055. PubMed ID: 32212026
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRCA-related ATM-mediated DNA double-strand break repair and ovarian aging.
    Turan V; Oktay K
    Hum Reprod Update; 2020 Jan; 26(1):43-57. PubMed ID: 31822904
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patients.
    Singer CF; Tan YY; Muhr D; Rappaport C; Gschwantler-Kaulich D; Grimm C; Polterauer S; Pfeiler G; Berger A; Tea MM
    Cancer Med; 2019 Apr; 8(4):1875-1881. PubMed ID: 30821131
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential implications on female fertility and reproductive lifespan in BRCA germline mutation women.
    de la Noval BD
    Arch Gynecol Obstet; 2016 Nov; 294(5):1099-1103. PubMed ID: 27561295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Germline BRCA variants, lifestyle and ovarian cancer survival.
    Gersekowski K; Delahunty R; Alsop K; Goode EL; Cunningham JM; Winham SJ; Pharoah P; Song H; Jordan S; Fereday S; DeFazio A; Friedlander M; Obermair A; ; ; Webb PM
    Gynecol Oncol; 2022 Jun; 165(3):437-445. PubMed ID: 35400525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Family history predictors of BRCA1/BRCA2 mutation status among Tunisian breast/ovarian cancer families.
    Riahi A; Ghourabi ME; Fourati A; Chaabouni-Bouhamed H
    Breast Cancer; 2017 Mar; 24(2):238-244. PubMed ID: 27025497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis.
    Oh M; Alkhushaym N; Fallatah S; Althagafi A; Aljadeed R; Alsowaida Y; Jeter J; Martin JR; Babiker HM; McBride A; Abraham I
    Prostate; 2019 Jun; 79(8):880-895. PubMed ID: 30900310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Baseline E(2) levels are higher in BRCA2 mutation carriers: a potential target for prevention?
    Kim J; Oktay K
    Cancer Causes Control; 2013 Mar; 24(3):421-6. PubMed ID: 23271408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ovarian cancer onset across different
    Marchetti C; Ataseven B; Cassani C; Sassu CM; Congedo L; D'Indinosante M; Cappuccio S; Rhiem K; Hahnen E; Lucci Cordisco E; Arbustini E; Harter P; Minucci A; Scambia G; Fagotti A
    Int J Gynecol Cancer; 2023 Feb; 33(2):257-262. PubMed ID: 36581488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BRCA mutation carriers do not have compromised ovarian reserve.
    Michaelson-Cohen R; Mor P; Srebnik N; Beller U; Levy-Lahad E; Eldar-Geva T
    Int J Gynecol Cancer; 2014 Feb; 24(2):233-7. PubMed ID: 24378620
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The first Japanese nationwide multicenter study of
    Enomoto T; Aoki D; Hattori K; Jinushi M; Kigawa J; Takeshima N; Tsuda H; Watanabe Y; Yoshihara K; Sugiyama T
    Int J Gynecol Cancer; 2019 Jul; 29(6):1043-1049. PubMed ID: 31263023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
    Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
    Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
    Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
    Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Germline breast cancer susceptibility gene mutations and breast cancer outcomes.
    Wang YA; Jian JW; Hung CF; Peng HP; Yang CF; Cheng HS; Yang AS
    BMC Cancer; 2018 Mar; 18(1):315. PubMed ID: 29566657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation.
    Vicus D; Finch A; Rosen B; Fan I; Bradley L; Cass I; Sun P; Karlan B; McLaughlin J; Narod SA;
    Gynecol Oncol; 2010 Aug; 118(2):155-9. PubMed ID: 20452659
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
    Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
    Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis.
    Le Page C; Rahimi K; Rodrigues M; Heinzelmann-Schwarz V; Recio N; Tommasi S; Bataillon G; Portelance L; Golmard L; Meunier L; Tonin PN; Gotlieb W; Yasmeen A; Ray-Coquard I; Labidi-Galy SI; Provencher D; Mes-Masson AM
    Gynecol Oncol; 2020 Feb; 156(2):377-386. PubMed ID: 31753525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not?
    Vos S; van Diest PJ; Moelans CB
    Crit Rev Oncol Hematol; 2018 Jul; 127():29-41. PubMed ID: 29891109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.
    Hyman DM; Zhou Q; Iasonos A; Grisham RN; Arnold AG; Phillips MF; Bhatia J; Levine DA; Aghajanian C; Offit K; Barakat RR; Spriggs DR; Kauff ND
    Cancer; 2012 Aug; 118(15):3703-9. PubMed ID: 22139894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.